Provided by Tiger Trade Technology Pte. Ltd.

Pliant Therapeutics, Inc.

1.04
-0.0150-1.43%
Post-market: 1.040.00000.00%19:30 EDT
Volume:402.81K
Turnover:418.71K
Market Cap:64.08M
PE:-0.69
High:1.07
Open:1.06
Low:1.03
Close:1.05
52wk High:1.95
52wk Low:1.02
Shares:61.91M
Float Shares:55.03M
Volume Ratio:1.23
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5000
EPS(LYR):-2.4336
ROE:-50.29%
ROA:-23.27%
PB:0.44
PE(LYR):-0.43

Loading ...

Pliant Therapeutics Q2 EPS USD -0.36

THOMSON REUTERS
·
Aug 12

Pliant Therapeutics, Inc. Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Pliant Therapeutics adds independent directors to strengthen R&D

TIPRANKS
·
Jul 14

Pliant Therapeutics Director Flavia Borellini Files Initial Beneficial Ownership Statement

Reuters
·
Jul 14

Pliant Therapeutics Appoints Flavia Borellini, Robert Iannone to Board

Reuters
·
Jul 13

Pliant Therapeutics Names Flavia Borellini, Ph.d. and Robert Iannone, M.d., M.s.c.e. to Board of Directors

THOMSON REUTERS
·
Jul 13

Pliant Therapeutics shareholders elect Coulie, Crowell, Krognes as Class III directors

Reuters
·
Jun 12

Pliant Therapeutics to present PLN-101095 trial data at ASCO meeting

Reuters
·
May 22

Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

TIPRANKS
·
May 13

Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)

TIPRANKS
·
May 12

Pliant Therapeutics Q1 net loss narrows on lower expenses

Reuters
·
May 12

Pliant Therapeutics doses first participant in FORTIFY expansion trial

TIPRANKS
·
Apr 30

Pliant doses first patient in Phase 1b FORTIFY trial of PLN-101095 combo therapy

Reuters
·
Apr 30

Pliant Therapeutics Announces First Patient Dosed in Fortify, the Phase 1B Indication Expansion Trial Evaluating Pln-101095 in Patients With Ici-Refractory Solid Tumors

THOMSON REUTERS
·
Apr 30

Pliant Therapeutics Inc - Enrollment Is Underway With Interim Data Expected in 2027

THOMSON REUTERS
·
Apr 30

Pliant Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 23

Pliant announces presentation of updated data from Phase 1 trial of PLN-101095

TIPRANKS
·
Apr 20

BRIEF-Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed

Reuters
·
Apr 19

Pliant presents updated Phase 1 PLN-101095 data in ICI-refractory solid tumors

Reuters
·
Apr 19

Pliant Therapeutics Announces Presentation of Updated Data From the Phase 1 Trial of Pln-101095 in Patients With Ici-Refractory Solid Tumors at the 2026 Aacr Annual Meeting

THOMSON REUTERS
·
Apr 19